References
Argento, E., Strathdee, S. A., Tupper, K., Braschel, M., Wood, E., & Shannon, K. (2017). Does psychedelic drug use reduce risk of suicidality? Evidence from a longitudinal community-based cohort of marginalised women in a Canadian setting. BMJ Open, 7(9), e016025. https://doi.org/10.1136/bmjopen-2017-016025.
Belouin, S. J., & Henningfield, J. E. (2018). Psychedelics: Where we are now, why we got here, what we must do. Neuropharmacology, 142, 7-19. https://doi.org/10.1016/j.neuropharm.2018.02.018.
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P. C. R., & Strassman, R. J. (2015). Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. Journal of Psychopharmacology (Oxford, England), 29(3), 289-299. https://doi.org/10.1177/0269881114565144.
Canal, C. E., & Murnane, K. S. (2016). The serotonin 5-HT2Creceptor and the non-addictive nature of classic hallucinogens. Journal of Psychopharmacology, 31(1), 127-143. https://doi.org/10.1177/0269881116677104.
Carhart-Harris, R. L., Erritzoe, D., Haijen, E., Kaelen, M., & Watts, R. (2017). Psychedelics and connectedness. Psychopharmacology, 235(2), 547-550. https://doi.org/10.1007/s00213-017-4701-y.
Chi, T., & Gold, J. A. (2020). A review of emerging therapeutic potential of psychedelic drugs in the treatment of psychiatric illnesses. Journal of the Neurological Sciences, 411, 116715. https://doi.org/10.1016/j.jns.2020.116715.
Davis, A. K., Agin-Liebes, G., España, M., Pilecki, B., & Luoma, J. (2021). Attitudes and Beliefs about the Therapeutic Use of Psychedelic Drugs among Psychologists in the United States. Journal of Psychoactive Drugs, 1-10. https://doi.org/10.1080/02791072.2021.1971343.
Dinis-Oliveira, R. J., Pereira, C. L., & Dias da Silva, D. (2019). Pharmacokinetic and Pharmacodynamic Aspects of Peyote and Mescaline: Clinical and Forensic Repercussions. Current Molecular Pharmacology, 12(3), 184-194. https://doi.org/10.2174/1874467211666181010154139.
Feduccia, A. A., & Mithoefer, M. C. (2018). MDMA-assisted psychotherapy for PTSD: Are memory reconsolidation and fear extinction underlying mechanisms? Progress in Neuro-Psychopharmacology and Biological Psychiatry, 84, 221-228. https://doi.org/10.1016/j.pnpbp.2018.03.003.
Gasser, P., Holstein, D., Michel, Y., Doblin, R., Yazar-Klosinski, B., Passie, T., & Brenneisen, R. (2014). Safety and Efficacy of Lysergic Acid Diethylamide-Assisted Psychotherapy for Anxiety Associated With Life-threatening Diseases. The Journal of Nervous and Mental Disease, 202(7), 513-520.
https://doi.org/10.1097/nmd.0000000000000113.
Hendricks, P. S., Thorne, C. B., Clark, C. B., Coombs, D. W., & Johnson, M. W. (2015). Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. Journal of Psychopharmacology, 29(3), 280-288. https://doi.org/10.1177/0269881114565653.
Hofmann, A. (2019). LSD, my problem child; and, Insights/outlooks. Beckley Foundation.
Johnson, M. W., Hendricks, P. S., Barrett, F. S., & Griffiths, R. R. (2019). Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. Pharmacology & Therapeutics, 197, 83-102. https://doi.org/10.1016/j.pharmthera.2018.11.010.
Malcolm, B., & Thomas, K. (2021). Serotonin toxicity of serotonergic psychedelics. Psychopharmacology.
https://doi.org/10.1007/s00213-021-05876-x.
Sanches, R. F., de Lima Osório, F., dos Santos, R. G., Macedo, L. R. H., Maia-de-Oliveira, J. P., Wichert-Ana, L., de Araujo, D. B., Riba, J., Crippa, J. A. S., & Hallak, J. E. C. (2016). Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression. Journal of Clinical Psychopharmacology, 36(1), 77-81.
https://doi.org/10.1097/jcp.0000000000000436.
Vollenweider, F. X., & Preller, K. H. (2020). Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders. Nature Reviews Neuroscience, 21(11), 611-624. https://doi.org/10.1038/s41583-020-0367-2.
Watts, R., Day, C., Krzanowski, J., Nutt, D., & Carhart-Harris, R. (2017). Patients’ Accounts of Increased “Connectedness” and “Acceptance” After Psilocybin for Treatment-Resistant Depression. Journal of Humanistic Psychology, 57(5), 520-564. https://doi.org/10.1177/0022167817709585.